Table 3.

Responses by BICR per RECIST 1.1

	Pooled RDE (5.6 mg/kg)
Characteristics	All pooled (n = 57)	Prior PBC and osimertinib (n = 44)
Confirmed ORR, % (n) [95% CI]	39 (22)	39 (17)
	[26.0–52.4]	[24.4–54.5]
BOR, n (%)
CR	1 (2)	1 (2)
PR	21 (37)	16 (36)
SD	19 (33)	13 (30)
PD	9 (16)	8 (18)
NE	7 (12)	6 (14)
DCR,a % (n) [95% CI]	72 (41)	68 (30)
	[58.5–83.0]	[52.4–81.4]
TTR, median (range), months	2.6 (1.2–5.4)	2.7 (1.2–5.4)
Duration of response, median (95% CI), months	6.9 (3.1–NE)	7.0 (3.1–NE)
Progression-free survival, median (95% CI), months	8.2 (4.4–8.3)	8.2 (4.0–NE)
Overall survival, median (95% CI), months	NE (9.4–NE)	NE (8.2–NE)

Abbreviation: PBC, platinum-based chemotherapy.

^aDCR = rate of confirmed BOR of CR, PR, or SD.